Translating exceptional science into health benefits for neuromuscular disease patients worldwide

Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development

Clinical Trials

Phase 1 biomarker data shows improvement of safety profiles of vamorolone over prednisolone for adrenal suppression, bone turnover, insulin resistance, and immune suppression. Learn more >

About vamorolone

Vamorolone enrollment in Phase 2a opens at Duke University; first DMD subjects enrolled.

Learn More


microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.

Learn More


Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be

Learn More